
|Articles|June 1, 2002
The potency/efficacy of the fluoroquinolones in community-acquired pneumonia
This article reviews the efficacy of fluoroquinolones for treating community-acquired pneumonia (CAP) and discusses clinical advantages of fluoroquinolones relative to other drug classes. Of 19 randomized, controlled trials comparing a fluoroquinolone with another agent or combination of agents in CAP, 6 trials have demonstrated superiority of the fluoroquinolone with respect to clinical and/or bacteriologic efficacy.
Advertisement
Newsletter
Get the latest industry news, event updates, and more from Managed healthcare Executive.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Cobenfy in Practice: Hope, Hurdles, and the Next Chapter in Schizophrenia Care
2
FDA Approves Gazyva for Lupus Nephritis in Adults
3
AI in Ophthalmology: The Key to the Present Success Includes a CPT Code. The Future? Agentic AI That Doesn’t Wait To Be Told What To Do | AAO 2025
4
Making Sense of the Eye Pain-Headache Connection | AAO 2025
5